Semaglutide Dosing Schedule: 0.25mg to 2.4mg Week by Week

One of the first things people notice about semaglutide is that they do not start on the dose that does most of the work. The therapeutic dose for weight management is 2.4mg once weekly, yet almost no one begins there. Instead, treatment opens at 0.25mg — a dose low enough that it produces relatively little weight loss on its own — and climbs in deliberate steps over roughly four months. To someone eager to see results, this can feel like an oddly slow start. It is not an accident of caution or a way of stretching out prescriptions. The slow climb, known as titration, is built into how the drug is designed to be used, and understanding why makes the whole schedule make sense.

This article walks through the standard week-by-week titration for semaglutide, explains the biology behind the gradual increase, notes how the weight-management schedule differs from the diabetes one, and describes what generally happens when a dose is not tolerated. It is educational, not personal medical advice — the actual schedule any individual follows is set and adjusted by a prescriber, and the numbers below describe the standard manufacturer labelling rather than a plan anyone should self-direct. For the broader science of how these medications work, the GLP-1 science pillar guide provides the full background this builds on.

The Standard Wegovy Titration, Week by Week

Semaglutide for weight management — sold as Wegovy — follows a fixed escalation schedule on its label. Treatment is divided into five dose levels, each held for four weeks before the next increase, so that the full therapeutic dose is reached at around week 17. The intervals are not arbitrary: four weeks is roughly the time it takes for the gastrointestinal system to adapt to a given dose before the next step is added.

Weeks	Weekly dose	Purpose of this step
Weeks 1–4	0.25 mg	Starter dose — introduces the drug; little weight effect by design
Weeks 5–8	0.5 mg	First escalation as the gut adapts
Weeks 9–12	1.0 mg	Mid-titration step
Weeks 13–16	1.7 mg	Penultimate step toward the target dose
Week 17 onward	2.4 mg	Full maintenance / therapeutic dose

A few features of this schedule are worth drawing out. The starting dose, 0.25mg, is explicitly a non-therapeutic dose — it is too low to produce the weight loss seen in the trials, and it is not meant to. Its only job is to let the body meet the drug gently. The dose then roughly doubles at each of the first steps before the more modest final increase to 2.4mg. The whole sequence takes a minimum of sixteen weeks to complete if every step goes smoothly, which means reaching the full dose is normally a four-month process, not a four-week one.

It is also worth saying clearly that this is the standard schedule, not a universal one. The label allows for flexibility, and prescribers use it. A person who tolerates each step easily follows the timeline above; a person who struggles at a particular level may stay there longer, or step back down, before trying to advance again. The schedule is a default that is meant to be individualised, and the four-week intervals are minimums rather than fixed deadlines.

Why Start Low and Go Slow

The logic of titration follows directly from how semaglutide works. The medication is a GLP-1 receptor agonist — an engineered, long-acting version of a gut hormone the body releases after eating. As Daniel Drucker's 2018 synthesis in Cell Metabolism sets out, one of GLP-1's core actions is to slow the rate at which the stomach empties its contents into the small intestine. That slowing is part of how the drug produces fullness: a stomach that empties more slowly stays distended longer, and the meal you have eaten keeps signalling satiety for longer. But the same slowed gastric emptying is also the direct source of the most common side effects — nausea, vomiting, and a general sense of early or excessive fullness — particularly in the first weeks at any given dose.

In other words, the principal side effects and the principal therapeutic effect come from the same mechanism. The nausea is, in a sense, the appetite-suppressing machinery overshooting before the body has adjusted to it. This is why the dose cannot simply be started at its target: jumping straight to 2.4mg would expose the gut to the full slowing effect all at once, and for most people that would produce side effects severe enough to make them stop. Titration sidesteps this by keeping the adaptation ahead of the dose. Each four-week step lets the gastrointestinal system habituate to the current level of slowing before more is added, so that the body is always meeting a tolerable increment rather than a sudden change.

Skipping or rushing titration is one of the most common reasons people experience side effects severe enough to stop treatment. The schedule exists precisely to keep the adaptation ahead of the dose — its slowness is the feature, not a flaw.

This is the central thing to understand about the schedule: the slow climb is doing protective work even when it feels like it is doing nothing. The large randomised trials that established semaglutide, including the STEP 1 trial led by John Wilding and published in the New England Journal of Medicine in 2021, used exactly this kind of stepwise escalation to 2.4mg, and in that trial the gastrointestinal side effects — though common — were generally mild to moderate and led only a small minority to discontinue. The titration schedule is part of why the drug is tolerable enough to be taken for the long periods its benefits require. The fuller arc of what to expect symptom-wise over these weeks is laid out in the GLP-1 side effects timeline.

How Ozempic Differs

A frequent source of confusion is that semaglutide is sold under more than one brand, with different dosing. Ozempic is semaglutide approved for type 2 diabetes; Wegovy is the same molecule approved, at higher doses, for weight management. They are the same drug, but the labelled dose ladders are not identical, and the distinction matters when reading dosing information online.

Ozempic's diabetes titration also begins at 0.25mg weekly for four weeks, then steps up to 0.5mg. From there it can be increased to 1.0mg and, on the current label, up to a maximum of 2.0mg weekly — a lower ceiling than Wegovy's 2.4mg. The diabetes schedule is oriented toward blood-sugar control, where the target dose is whatever achieves adequate glycaemic results and may be lower than the dose used to maximise weight loss. The weight-management ladder, by contrast, is designed to reach the higher 2.4mg dose that produced the weight loss seen in STEP 1. Because the brands overlap in their lower steps but diverge at the top, it is easy to mistake one schedule for the other; the practical point is that the right schedule depends on which product and which indication a prescriber is treating, not on the molecule alone.

There is also an oral form of semaglutide (Rybelsus), taken daily rather than weekly, with its own separate dose ladder and specific instructions about taking it on an empty stomach. The week-by-week numbers in this article refer to the injectable weight-management schedule. Whichever form is involved, the underlying principle is the same: start low, raise in steps, and let tolerance build.

What To Do If a Dose Isn't Tolerated

Not everyone moves smoothly up the ladder, and the schedule anticipates this. If side effects at a particular step are difficult — persistent nausea, vomiting, or fullness that interferes with eating adequately — the standard response is not to push through regardless. The label itself provides for delaying the next increase, holding at the current dose for longer, or temporarily stepping back down to the previous dose until symptoms settle, before attempting to advance again. None of these is a failure of treatment; they are the schedule working as intended.

Several practical strategies help side effects settle enough to stay on the schedule, and they follow from the slowed-gastric-emptying mechanism. Smaller meals eaten more slowly produce less nausea than large meals eaten quickly, because they ask less of a stomach that is already emptying slowly. Reducing high-fat foods helps, since fat empties especially slowly. Staying well hydrated addresses both nausea and the constipation that titration can also bring. These approaches are set out in more detail in managing nausea on GLP-1, and they are often the difference between tolerating a step and having to pause at it.

Two further points deserve emphasis. First, the technique and rotation of the weekly injection itself can affect comfort and absorption; the practicalities of where and how to inject are covered in semaglutide injection sites. Second, some people never reach 2.4mg at all — and that is a legitimate outcome rather than a shortfall. A meaningful number of people achieve good results and adequate tolerability at 1.0mg or 1.7mg, and a prescriber may decide that the right maintenance dose for a given person is below the maximum. The full-dose figure is a target, not an obligation, and the question of what dose to settle on for the long term is discussed in the GLP-1 maintenance dose.

What the Dose Is Actually Doing

It helps to remember what the rising dose is buying. The appetite effect of semaglutide is not a single action but several working together. Beyond the slowed gastric emptying already described, the drug acts on the hypothalamus to bias the brain's appetite circuits toward satiety, and — as Liselotte van Bloemendaal and colleagues showed in 2014 using functional MRI — it reduces the reward system's response to food cues, which is the neurobiological basis of the quieting of "food noise" that many people describe. Higher doses engage these circuits more fully, which is broadly why the larger 2.4mg dose produced more weight loss in trials than the lower doses used for diabetes. Titration is the controlled approach to that fuller engagement.

This also explains why the early weeks can feel underwhelming on the scale. At 0.25mg and 0.5mg, the drug is present and the body is adapting, but the dose is below the level that drives substantial weight loss. People who expect dramatic early results sometimes worry that the medication "isn't working" during titration. In most cases it is working exactly as designed — building tolerance so that the doses that do move weight can be reached and sustained. Judging the medication by the first month is, in effect, judging it before it has been given its therapeutic dose.

Why the Schedule Reflects a Chronic-Disease Model

The titration schedule is the opening phase of what is, for most people, a long-term treatment. The trials make this clear. The STEP 4 trial, led by Domenica Rubino and published in JAMA in 2021, took people through the titration and an initial period on the drug, then randomised them either to continue semaglutide or to switch to placebo. Those who continued kept losing weight; those switched to placebo regained roughly two-thirds of what they had lost over the following year. Wilding's STEP 1 trial extension, published in 2022, found the same pattern after the drug was withdrawn. The reason, as Priya Sumithran's landmark 2011 work documented, is that the body defends a higher weight through elevated hunger hormones and suppressed satiety signalling that persist long after weight is lost — the medication counters that defence while it is present, and the defence reasserts itself when it is removed.

Seen in that light, the careful titration at the start is the front end of ongoing management, much as one would expect for a chronic condition like high blood pressure rather than a short course of treatment. It is worth situating semaglutide within the wider class as well: tirzepatide, the dual GLP-1/GIP agonist studied in Ania Jastreboff's SURMOUNT-1 trial (2022), uses its own analogous stepwise titration for the same reasons, and the broader landscape of these medications is mapped across the GLP-1 science cluster. Before starting any of them, a practical readiness checklist is set out in the GLP-1 checklist before starting.

The schedule, in short, is not a hurdle to get past on the way to the "real" dose. It is the mechanism by which the real dose becomes usable at all. Starting low and climbing slowly is how a drug whose therapeutic effect and side effects share a single mechanism is made tolerable enough to take for as long as its benefits last. The specific weeks and milligrams matter less than the principle behind them — and the specifics, in every individual case, belong with a prescriber who can adjust the pace to the person.